Neurogene Inc. — Director's Dealing 2021

Aug 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2021-08-24

Reporting Person: DRACHMAN JONATHAN G (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-24	Common Stock	P	100000	$6.111	Acquired	2348686	Direct
2021-08-25	Common Stock	P	25000	$6.449	Acquired	25000	Indirect
2021-08-25	Common Stock	P	25000	$6.449	Acquired	25000	Indirect

Footnotes

F1: Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.1099 and the highest price at which shares were purchased was $6.1482. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

F2: Represents the weighted average purchase price. The lowest price at which shares were purchased was $6.09 and the highest price at which shares were purchased was $6.60.

F3: These securities are held by a spousal limited access trust of which the Reporting Person is the primary beneficiary.

F4: These securities are held by a spousal limited access trust of which the Reporting Person's spouse is the primary beneficiary.